Usage Examples
- The Q3D risk assessment traced vanadium to the stainless steel reactor and landed below the control threshold, so no routine release test was added.
- Class 1 elements came in under 30 percent of the PDE across all three production lots, so we are not adding a drug product specification.
- That excipient is mined, so the elemental impurity variability argues for more data than three lots before we lean on the control threshold.
What is Elemental Impurity?
Elemental impurities are inorganic contaminants, principally metals such as arsenic, cadmium, mercury and lead, that reach a drug product from catalysts, drug substances, excipients, water, manufacturing equipment or container closure systems rather than being added for therapeutic benefit.
Elemental impurities exist as a regulatory category because metals carry toxicity without carrying benefit. ICH Q3D(R2), adopted at Step 4 on 26 April 2022, states it directly: elemental impurities do not provide any therapeutic benefit to the patient, so their levels in the drug product should be controlled within acceptable limits. The guideline therefore sets a Permitted Daily Exposure for each element of toxicological concern and applies a risk-based approach to controlling it.
Elemental impurities are assessed at the drug product level, with the drug substance, excipients, water, manufacturing equipment and the container closure system all treated as contributing sources. Q3D(R2) applies to new finished drug products and to new drug products containing existing drug substances. It excludes herbal products, radiopharmaceuticals, vaccines, blood derivatives, gene, cell and tissue therapies, and drug products used during clinical research stages of development.
Elemental impurities are managed in practice through a three-part assessment: identify the sources, evaluate the observed or predicted level against the PDE, then summarize and document whether the controls already built into the process are sufficient. The pivot point is the control threshold, defined as 30 percent of the established PDE. Stay consistently below it across all sources and no additional controls are required. Exceed it and controls must guarantee the PDE is not exceeded.
Not to be confused with
- Heavy metals
- a colloquial grouping by density. Q3D classifies by toxicity and probability of occurrence instead, which is why low-density lithium and the metalloids arsenic and selenium are in scope while iron and zinc are among the elements Q3D does not address.
- Organic impurities (ICH Q3A/Q3B)
- Q3A and Q3B govern organic impurities and degradation products. Q3D governs elements. Q3D itself points back to Q3A when an element has a high PDE but still matters from a pharmaceutical quality perspective.
- Nitrosamine impurity
- an organic, process-formed contaminant that appears nowhere in Q3D's element list. A completed Q3D risk assessment provides zero coverage of nitrosamine risk, and treating it as impurity work already done is a common gap.
- Control threshold
- not the limit you must meet. The PDE is the limit; the control threshold is 30 percent of it and only decides whether additional controls are needed. Passing the control threshold is a conclusion about controls, not a specification result.
The obligations sit in ICH Q3D(R2), enforced through the CGMP requirement to hold scientifically sound specifications.
What you must do
- 1Confirm the product is in scope before starting, since the guideline covers new finished drug products and new products containing existing drug substances, and excludes herbals, radiopharmaceuticals, vaccines, blood derivatives, gene, cell and tissue therapies, and clinical research materialICH Q3D(R2) Section 2
- 2Evaluate the four Class 1 elements (As, Cd, Hg, Pb) across all potential sources and all routes of administration, extend to Class 2A (Co, Ni, V), and include Class 2B only where intentionally addedICH Q3D(R2) Section 4
- 3Compare the total expected level from all sources against the control threshold of 30 percent of the established PDE, and document the summary identifying the elemental impurities, their sources, and the controls and acceptance criteriaICH Q3D(R2) Section 5.6
- 4Where the level may exceed the control threshold, implement additional measures, whether process modification, in-process or upstream controls, specification limits on excipients, drug substance or drug product, or container closure selection, and describe them in the submissionICH Q3D(R2) Section 6
- 5Establish scientifically sound specifications and test procedures for every element carried into the control strategy, so the finished product conforms to its declared standards of quality and purity21 CFR 211.160(b)
Common mistakes
Treating the risk assessment as a testing exercise
Q3D lists six acceptable data sources, and only two of them are testing: prior knowledge, published literature, data from similar processes, supplier information, testing of components, and testing of the drug product. Teams that jump straight to finished-product ICP-MS buy a number that does not answer the sourcing question and still have to write the assessment.
Applying the control threshold to a single batch
at the time of submission, and absent other justification, the level and variability of an elemental impurity should be established from three representative production scale lots or six representative pilot scale lots, and mined excipients may need more data still. One result cannot support a claim of consistently less than 30 percent.
Assuming a supplier certificate closes the assessment
Q3D is assessed on the drug product, not the drug substance. Contributions from container closure systems and manufacturing equipment must be accounted for before the maximum permitted concentration in the remaining components is calculated, so a clean API certificate leaves most of the assessment unwritten.
When This Matters
- The Q3D risk assessment traced vanadium to the stainless steel reactor and landed below the control threshold, so no routine release test was added.
- Class 1 elements came in under 30 percent of the PDE across all three production lots, so we are not adding a drug product specification.
- That excipient is mined, so the elemental impurity variability argues for more data than three lots before we lean on the control threshold.
Frequently Asked Questions
ICH Q3D(R2) covers 24 elements in four classes. Class 1 is arsenic, cadmium, mercury and lead, evaluated across all potential sources and routes. Class 2A is cobalt, nickel and vanadium. Class 2B, which includes silver, gold, iridium, osmium, palladium, platinum, rhodium, ruthenium, selenium and thallium, is assessed only when intentionally added. Class 3 is barium, chromium, copper, lithium, molybdenum, antimony and tin.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
